European market fragmentation and the lack of cooperation between the authorities responsible for setting prices and reimbursement are the main barriers to creating an efficient policy on rare diseases. This was the message sent out on Wednesday 22 February by the Eurordis organisation, during a conference on rare diseases.
A disease is considered “rare” if it affects fewer than 5 out of 10,000 people. Little is known about these diseases due to their rarity and their medical,...